---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-025772"
form_type: "8-K"
ticker: "FBRX"
cik: "0001419041"
company_name: "Forte Biosciences, Inc."
filed_at: "2022-02-02T23:59:59+00:00"
generated_at: "2026-06-27T12:16:40.241418+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "medium"
source: SEC EDGAR
---

# Forte Biosciences terminates patent license agreement with NIAID, effective April 2, 2022

## Summary
- Terminated Patent License Agreement with National Institute of Allergy and Infectious Diseases (NIAID).
- Termination effective April 2, 2022.
- Company will have no future payment obligations under the Agreement.

## SEC filing metadata
- accession: 0001193125-22-025772
- form_type: 8-K
- ticker: FBRX
- cik: 0001419041
- company_name: Forte Biosciences, Inc.
- filed_at: 2022-02-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: medium
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1419041/000119312522025772/0001193125-22-025772-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1419041/000119312522025772/d303337d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-025772
- JSON: https://secwatch.observer/filing/0001193125-22-025772.json
- Plain text: https://secwatch.observer/filing/0001193125-22-025772.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.